This article provides an overview of the global nanomedicine market, highlighting key players, emerging technologies, and the challenges and opportunities that influence its growth and commercialization in the healthcare sector.
Nanomedicines are nanotechnology-based drug products developed by combining suitable nanocarriers with active pharmaceutical ingredients (APIs) to treat, diagnose, or prevent various diseases.
The U.S. Food and Drug Administration (FDA) defines nanomedicines as products with at least one dimension in the nanoscale range (1–100 nm) that exhibit distinct chemical, physical, or biological properties compared to larger-scale counterparts.
The nanoscale structure and surface properties of nanomedicines enhance drug solubility, stability, selectivity, targeted delivery, and bioavailability, thereby improving efficacy in treating complex diseases such as cancer, cardiovascular disorders, and neurological conditions.1
Market Overview
The global nanomedicine market, valued at approximately USD 189.55 billion in 2023, is projected to exceed USD 562.95 billion by 2033, reflecting a compound annual growth rate (CAGR) of 11.5 % from 2024 to 2033.2
This growth is driven by advancements in nano-pharmaceuticals and the increasing demand for more effective treatments for cancer, immune system diseases, nervous system disorders, and infectious diseases like AIDS.
A significant trend in this sector is the focus on personalized medicine, where nano-pharmaceuticals facilitate tailored therapies based on individual genetic profiles. This approach improves treatment outcomes through targeted drug delivery, reducing side effects.
For instance, nanomedicines like Doxil and Abraxane have enhanced efficacy in cancer treatment by selectively targeting cancer cells, minimizing damage to healthy tissues, and lowering toxic side effects.
With over 500 active clinical trials involving nanoparticles and more than 100 FDA-approved nanomedicines, the sector is attracting significant investment from major pharmaceutical companies.3
Key Players in the Nanomedicine Market
Several companies and research institutions are at the forefront of nanomedicine development, driving healthcare innovation through new therapies and diagnostics.
Bristol-Myers Squibb
As one of the world’s largest pharmaceutical companies, Bristol Myers Squibb actively develops nanotechnology-based drug delivery systems. It is a leading patent filer in drug delivery nanoparticles, with a focus on oncology, immunology, hematology, and fibrotic diseases.
The company’s use of liposomes to enhance drug targeting, particularly in cancer treatment, has resulted in innovative formulations like Abraxane, which uses nanoparticle-bound albumin for treating metastatic breast cancer.4,5
Moderna
Moderna, a pioneer in mRNA therapeutics, gained global recognition for developing the COVID-19 mRNA vaccine. Its innovative use of lipid nanoparticles to encapsulate mRNA represents a significant advancement in nanomedicine, providing a framework for future therapies targeting various infectious diseases and cancers.6
Nanobiotix
Nanobiotix, a late-stage clinical biotechnology firm based in France, specializes in developing nanotechnology-based treatments for cancer. Its flagship product, NBTXR3, enhances radiotherapy by increasing radiation absorption in tumor cells, improving treatment outcomes with minimal side effects. It is undergoing clinical trials for non-small cell lung and head and neck cancer.7
Generation Bio
Generation Bio is another key player focusing on genetic medicines. Its proprietary cell-targeted lipid nanoparticle (ctLNP) technology enables selective targeting of therapeutic agents to specific tissues while minimizing off-target effects. This innovative approach has significant potential for in vivo cell therapies, such as reprogramming T cells within the patient’s body.8
Jazz Pharmaceuticals
Jazz Pharmaceuticals is a global biopharmaceutical specializing in oncology and neuroscience. Its FDA-approved product, Vyxeos™, is a liposomal formulation combining daunorubicin and cytarabine, indicated for treating therapy-related acute myeloid leukemia. This liposomal delivery system enhances the efficacy of cancer treatment while reducing toxicity compared to traditional drug administration.9
Cytiva
Other notable players include Ratiopharm, which markets the nanoparticle-bound albumin product Pazenir for various cancers, and Pacira, known for ZILRETTA, the first non-opioid treatment for osteoarthritis knee pain using extended-release microsphere technology.12,13
Recent Developments in the Nanomedicine Market
The nanomedicine market is evolving through several emerging technologies that are reshaping the future of healthcare.
On-Site Production of Nanomedicines for Real-Time Treatments
One of the most promising areas of development is the on-site production of nanomedicines. A recent study by researchers at the University of Oklahoma explored tools designed for producing nanomedicines, including vaccine formulations, directly at the point of care.
This approach addresses the limitations of centralized facilities, shipping challenges, and extreme cold storage requirements experienced during the COVID-19 pandemic.
The research team utilized components from 3D printers to create a T-mixer device that facilitates mixing fluid streams containing nanomedicine building blocks and their payloads.
This innovative system not only enhances the accessibility and efficiency of nanomedicine production but can also revolutionize personalized medicine by enabling real-time production of tailored treatments, ultimately improving patient outcomes and reducing the logistical complexities associated with traditional manufacturing processes.14
World’s First Regulatory Guidelines to Accelerate Clinical Translation
While technological advancements are crucial in nanomedicine, standardized frameworks are equally important for improving development and efficacy.
For example, despite recent successes with chemotherapy and vaccine-based nanomedicines, particularly lipid nanoparticles used in mRNA vaccines during the COVID-19 pandemic, clinical translation remains limited relative to research volume.
To address this, a global team of experts established “the DELIVER guidelines,” the world’s first research quality standards designed to reduce costs and accelerate the development of advanced nanomedicine treatments.
These guidelines offer recommendations across various phases, including design, experimentation, manufacturing, preclinical, clinical, regulatory, and business stages, thus maximizing clinical translation potential.
The DELIVER framework will provide essential principles for researchers, clinicians, and regulatory bodies to navigate translational challenges and minimize delays, facilitating personalized therapies tailored to individual patient needs and offering renewed hope for innovative medical solutions.15,16
Challenges in the Nanomedicine Market
The nanomedicine market faces significant challenges that hinder the transition from research to clinical applications.
Despite extensive studies on nanoformulations, only a small fraction progress to market assessments, with even fewer receiving final approval; reports indicate that less than 10 % of basic scientific research successfully translates into clinical applications. This gap, often referred to as the “valley of death,” makes the shift from laboratory to market costly and time-consuming, ultimately increasing healthcare expenses.
Several factors contribute to these challenges. The discrepancy between the in vivo and in vitro behavior of nanoparticles complicates understanding their clinical effectiveness. Tumor complexity and heterogeneity also hinder nanoformulation efficacy, as different tumors display varying gene expression profiles and drug resistance. Moreover, the multifaceted nature of some formulations adds complexity to the approval process, impeding the advancement of nanomedicines to market.
The threat of failure is significant in this landscape, as exemplified by BIND Therapeutics Inc., which declared bankruptcy in 2013 after its promising anticancer nanomedicine, BIND-014, failed to demonstrate efficacy in larger clinical trials despite initial success.
Opportunities for Growth and Development
Despite these challenges, opportunities for growth and development exist in the nanomedicine sector. The market for nanopharmaceuticals is anticipated to advance over the next five years, driven by innovations in bionanotechnology and nanoengineering. Key drivers for development include the establishment of clearer guidelines for nanotechnology-based drugs, increased government funding, and stronger collaboration between startups and established pharmaceutical companies.
To unlock the full potential of nanomedicines, stakeholders must advocate for adaptable intellectual property and regulatory frameworks tailored to the sector’s unique needs. Additionally, prioritizing long-term strategic planning over short-term gains will be essential for navigating the complexities of the nanomedicine landscape and ensuring successful market integration.17
References and Further Reading
- Shan, X., Gong, X., Li, J., Wen, J., Li, Y., Zhang, Z. (2022). Current approaches of nanomedicines in the market and various stage of clinical translation. Acta pharmaceutica Sinica. B. https://doi.org/10.1016/j.apsb.2022.02.025
- Precedence Research. (2024). Nanomedicine Market Size, Share, and Trends 2024 to 2034. [Online] Precedence Research. Available at: https://www.precedenceresearch.com/nanomedicine-market
- Liu, Q., Zou, J., Chen, Z., He, W., Wu, W. (2023). Current research trends of nanomedicines. Acta Pharmaceutica Sinica. https://doi.org/10.1016/j.apsb.2023.05.018
- Global Data. (2024). Leading innovators in drug delivery nanoparticles for the pharmaceutical industry. [Online] Pharmaceutical Technology. Available at: https://www.pharmaceutical-technology.com/data-insights/innovators-iot-nanoparticles-for-drug-delivery-pharmaceutical/
- Bristol-Myers Squibb. (2021). It’s not all smiles in drug development. [Online] Bristol-Myers Squibb. Available at: https://www.bms.com/life-and-science/science/unusual-liposome-image-during-drug-development.html
- Huang, X., Kong, N., Zhang, X., Cao, Y., Langer, R., Tao, W. (2022). The landscape of mRNA nanomedicine. Nature Medicine. https://doi.org/10.1038/s41591-022-02061-1
- Nanobiotix. (2024). A new standard in radiation oncology. [Online] Nanobiotix. Available at: https://nanobiotix.com/pipeline/
- Generation Bio. (2024). It’s time to unlock the full potential of genetic medicine. [Online] Generation Bio. Available at: https://generationbio.com/our-science
- Jazz Pharmaceuticals. (2022). Understanding treatment with VYXEOS, an advancementa,b in secondary AML therapy. [Online] Jazz Pharmaceuticals. Available at: https://vyxeos.com/
- Cytiva. (2024). NanoAssemblr™ commercial formulation system. [Online] Cytiva. Available at: https://www.cytivalifesciences.com/en/us/shop/lipid-nanoparticle-instruments-and-reagents/nanoparticle-formulation-systems/nanoassemblr-commercial-formulation-system-p-45337?srsltid=AfmBOopKpeQb_v_sVLMmejpjM2IYsBz–Qi79zKTKzDvPPr9L6WDwCgH
- Cytiva. (2024). Unleash The Potential Of RNA-LNPS Together. [Online] Cytiva. Available at: https://www.precisionnanosystems.com/
- European Medicines Agency. (2024). Pazenir. [Online] EMA. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/pazenir
- Pacira Pharmaceuticals. (2024). A non-opioid option for significant extended relief of OA knee pain. [Online] Pacira Pharmaceuticals. https://www.pacira.com/products/zilretta
- Young, H., He, Y., Joo, B., Ferguson, S., Demko, A., Butterfield, SK., Lowe, J., Mjema, NF., Sheth, V., Whitehead, L., Ruiz-Echevarria, MJ., Wilhelm, S. (2024). Toward the Scalable, Rapid, Reproducible, and Cost-Effective Synthesis of Personalized Nanomedicines at the Point of Care. Nano letters. https://doi.org/10.1021/acs.nanolett.3c04171
- Mansfield, A. (2024). Global experts help nanomedicines DELIVER on healthcare promise. [Online]. The University of South Australia. Available at: https://www.unisa.edu.au/media-centre/Releases/2024/global-experts-help-nanomedicines-deliver-on-healthcare-promise/
- Joyce, P., et al. (2024). A translational framework to DELIVER nanomedicines to the clinic. Nature Nanotechnology. https://doi.org/10.1038/s41565-024-01754-7
- Farjadian, F., Ghasemi, A., Gohari, O., Roointan, A., Karimi, M., Hamblin, MR. (2019). Nanopharmaceuticals and nanomedicines currently on the market: challenges and opportunities. Nanomedicine. https://doi.org/10.2217/nnm-2018-0120
News
New mpox variant can spread rapidly across borders
International researchers, including from DTU National Food Institute, warn that the ongoing mpox outbreak in the Democratic Republic of the Congo (DRC) has the potential to spread across borders more rapidly. The mpox virus [...]
How far would you trust AI to make important decisions?
From tailored Netflix recommendations to personalized Facebook feeds, artificial intelligence (AI) adeptly serves content that matches our preferences and past behaviors. But while a restaurant tip or two is handy, how comfortable would you [...]
Can AI Really Think? Research Reveals Gaps in Logical Execution
While AI models can break down problems into structured steps, new research reveals they still fail at basic arithmetic and fact-checking—raising questions about their true reasoning abilities. Large Language Models (LLMs) have become indispensable [...]
Scientists Just Made Cancer Radiation Therapy Smarter, Safer, and More Precise
Scientists at UC San Francisco have developed a revolutionary cancer treatment that precisely targets tumors with radiation while sparing healthy tissues. By using a KRAS-targeting drug to mark cancer cells and attaching a radioactive [...]
Superbugs Are Losing to Science, Light, and a Little Spice
Texas A&M researchers have found that curcumin, when activated by light, can weaken antibiotic-resistant bacteria, restoring the effectiveness of conventional antibiotics. Curcumin: A Surprising Ally Against Superbugs In 2017, a woman admitted to a [...]
New Research Shatters the Perfect Pitch Myth
For decades, people believed absolute pitch was an exclusive ability granted only to those with the right genetics or early music training. But new research from the University of Surrey proves otherwise. It’s been [...]
Why Some Drinkers Suffer Devastating Liver Damage While Others Don’t
A study from Keck Medicine of USC found that heavy drinkers with diabetes, high blood pressure, or a large waistline are up to 2.4 times more likely to develop advanced liver disease. These conditions may amplify [...]
“Good” Cholesterol Could Be Bad for Your Eyes – New Study Raises Concerns
‘Good’ cholesterol may be linked to an increased risk of glaucoma in individuals over 55, while, paradoxically, ‘bad’ cholesterol may be associated with a lower risk. These findings challenge conventional beliefs about factors that [...]
Reawakening Dormant Nerve Cells: Groundbreaking Neurotechnology Restores Motor Function
A new electrical stimulation therapy for spinal muscle atrophy (SMA) has shown promise in reactivating motor neurons and improving movement. In a pilot clinical trial, three patients who received spinal cord stimulation for one [...]
AI’s Energy Crisis Solved? A Revolutionary Magnetic Chip Could Change Everything
AI is evolving at an incredible pace, but its growing energy demands pose a major challenge. Enter spintronic devices—new technology that mimics the brain’s efficiency by integrating memory and processing. Scientists in Japan have [...]
Nanotechnology for oil spill response and cleanup in coastal regions
(Nanowerk News) Cleaning up after a major oil spill is a long, expensive process, and the damage to a coastal region’s ecosystem can be significant. This is especially true for the world’s Arctic region, [...]
The Role of Nanotechnology in Space Exploration
Nanotechnology, which involves working with materials at the atomic or molecular level, is becoming increasingly important in space exploration. By improving strength, thermal stability, electrical conductivity, and radiation resistance, nanotechnology is helping create lighter, more [...]
New Study Challenges Beliefs About CBD in Pregnancy, Reveals Unexpected Risks
CBD is gaining popularity as a remedy for pregnancy symptoms like nausea and anxiety, but new research suggests it may not be as safe as many believe. A study from McMaster University found that [...]
Does COVID increase the risk of Alzheimer’s disease?
Scientists discover that even mild COVID-19 can alter brain proteins linked to Alzheimer’s disease, potentially increasing dementia risk—raising urgent public health concerns. A recent study published in the journal Nature Medicine investigated whether both mild and [...]
New MRI Study Reveals How Cannabis Alters Brain Activity and Weakens Memory
A massive new study sheds light on how cannabis affects the brain, particularly during cognitive tasks. Researchers analyzed over 1,000 young adults and found that both heavy lifetime use and recent cannabis consumption significantly reduced brain [...]
How to Assess Nanotoxicity: Key Methods and Protocols
With their high surface area and enhanced physicochemical properties, nanomaterials play a critical role in drug delivery, consumer products, and environmental technologies. However, their nanoscale dimensions enable interactions with cellular components in complex and [...]
